GRAIL CFO Sells Over $480,000 in Shares

Aaron Freidin reduces stake in cancer detection company by 3%

Mar. 4, 2026 at 3:07am

Got story updates? Submit your updates here. ›

GRAIL, Inc. (NASDAQ:GRAL) Chief Financial Officer Aaron Freidin sold 9,573 shares of the company's stock on Monday, March 2nd. The shares were sold at an average price of $50.17, for a total transaction value of $480,277.41. Following the sale, Freidin still owns 309,622 shares of GRAIL stock, valued at approximately $15.5 million.

Why it matters

The sale represents a 3% decrease in Freidin's ownership stake in GRAIL, a biotechnology company focused on early cancer detection through a multi-cancer blood test. As a key executive, Freidin's stock transactions can provide insight into the company's financial health and leadership's confidence in its future prospects.

The details

Freidin's sale of 9,573 GRAIL shares was disclosed in a filing with the Securities and Exchange Commission. The shares were sold at an average price of $50.17, generating total proceeds of $480,277.41. After the transaction, Freidin continues to directly own 309,622 shares of GRAIL stock, valued at approximately $15.5 million based on the current share price.

  • The share sale transaction occurred on Monday, March 2, 2026.

The players

Aaron Freidin

The Chief Financial Officer of GRAIL, Inc.

GRAIL, Inc.

A biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test.

Got photos? Submit your photos here. ›

The takeaway

The CFO's stock sale, while representing a 3% reduction in his ownership stake, does not necessarily indicate any broader concerns about GRAIL's prospects. Insider transactions can have various motivations, and investors should consider the sale in the context of the company's overall financial health and strategic direction.